Sign In
Buy CMRX
$8.54
+0 (+0%)
At Close: Jul 18, 2025
Here's Why Momentum in Chimerix (CMRX) Should Keep going
09:50am, Thursday, 20'th Feb 2025
Chimerix (CMRX) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Tuesday, 18'th Feb 2025
DURHAM, N.C., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on February 12, 2025, the Compensation Committee of Chimerix's Board of Directors granted inducement awards
CMRX Stock Skyrockets in 3 Months: Here's What You Should Know
11:47am, Friday, 31'st Jan 2025
Chimerix stock surges 324% in three months following NDA submission for high-grade glioma drug, dordaviprone, for accelerated approval in the United States.
Chimerix to Present at JonesTrading Virtual Precision Medicine Symposium
04:15pm, Wednesday, 29'th Jan 2025
DURHAM, N.C., Jan. 29, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ: CMRX), a biopharmaceutical company whose mission it is to develop medicines that meaningfully improve and extend the lives of patients
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 24'th Jan 2025
DURHAM, N.C., Jan. 24, 2025 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on January 17, 2025, the Compensation Committee of Chimerix's Board of Directors granted inducement awards
Secures Access of Up To $30 Million to Support Potential Launch Through Silicon Valley Bank Credit Facility Secures Access of Up To $30 Million to Support Potential Launch Through Silicon Valley Bank
Chimerix: Big News, Big Moves, So Maybe Now's The Time To Buy
02:19pm, Wednesday, 11'th Dec 2024
Chimerix, Inc.'s dordaviprone shows promise in treating H3 K27M-positive glioma, with a potential FDA approval and commercial launch by Q3 2025. CMRX's strong clinical data and high unmet need in diff
Potential Approval in Q3 2025 in Recurrent H3 K27M-Mutant Diffuse Glioma Submission Plan Follows Productive and Collaborative Pre-NDA Interactions with FDA Company to Host Conference Call on Tuesday,
Chimerix Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
04:01pm, Friday, 06'th Dec 2024
DURHAM, N.C., Dec. 06, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on December 2, 2024, the Compensation Committee of Chimerix's Board of Directors granted inducement awards
Chimerix, Inc. (CMRX) Q3 2024 Earnings Call Transcript
09:34pm, Thursday, 07'th Nov 2024
Chimerix, Inc. (NASDAQ:CMRX ) Q3 2024 Earnings Call November 7, 2024 8:30 AM ET Company Participants Will O'Connor - Investor Relations Mike Andriole - President and Chief Executive Officer Josh Allen
Chimerix (CMRX) Reports Q3 Loss, Lags Revenue Estimates
09:35am, Thursday, 07'th Nov 2024
Chimerix (CMRX) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.27 per share a year ago.
Chimerix to Report Third Quarter 2024 Financial Results and Provide an Operational Update on November 7, 2024
07:00am, Friday, 01'st Nov 2024
DURHAM, N.C., Nov. 01, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), a biopharmaceutical company whose mission is to develop medicines that meaningfully improve and extend the lives of patients fa
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:31pm, Friday, 18'th Oct 2024
DURHAM, N.C., Oct. 18, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on October 16, 2024, the Compensation Committee of Chimerix's Board of Directors granted an inducement awar
Chimerix Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
04:05pm, Friday, 30'th Aug 2024
DURHAM, N.C., Aug. 30, 2024 (GLOBE NEWSWIRE) -- Chimerix (NASDAQ:CMRX), today announced that on August 20, 2024, the Compensation Committee of Chimerix's Board of Directors granted an inducement award
Chimerix (CMRX) Reports Q2 Loss, Misses Revenue Estimates
09:15am, Tuesday, 13'th Aug 2024
Chimerix (CMRX) came out with a quarterly loss of $0.23 per share in line with the Zacks Consensus Estimate. This compares to loss of $0.21 per share a year ago.
